Reuters logo
BRIEF-JCR Pharmaceuticals to initiate development of JR-162
February 23, 2017 / 7:16 AM / 8 months ago

BRIEF-JCR Pharmaceuticals to initiate development of JR-162

Feb 23 (Reuters) - JCR Pharmaceuticals Co Ltd :

* Says it plans to initiate development of a new drug candidate, JR-162

* Says JR-162 is a blood-brain barrier (BBB)-penetrating acid alpha-glucosidase (GAA) for treating Pompe disease which uses J-Brain Cargo, JCR’s BBB penetration technology

Source text in Japanese: goo.gl/Pf2eYc

Further company coverage: (Beijing Headline News)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below